Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.

Participants needed: 880
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Diwakar DavarUpdated: Apr 16, 2026Locations: 1
Eligibility criteria

Able to understand and willing to sign a written informed consent document. [+14]

Participant unable to receive nivolumab (or pembrolizumab) due to prior allergic... [+2]

Read more
Status: Recruiting

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

This study is to determine if Healthy Donor FMT (hdFMT) improves the body's ability to fight cancer in patients with relapsed/refractory PD-L1 Positive NSCLC.

Participants needed: 26
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Diwakar DavarUpdated: Mar 23, 2026Locations: 1
Eligibility criteria

Not a woman of childbearing potential (WOCBP); OR [+37]

Diagnosis of NSCLC histologies other than squamous and/or adenocarcinoma histolo... [+44]

Read more
Status: Recruiting

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A\*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker.

Participants needed: 44
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Diwakar DavarUpdated: Feb 27, 2026Locations: 3
Eligibility criteria

If HLA-A status is not known, blood for HLA-A testing must be submitted during S... [+16]

History of severe hypersensitivity reactions (eg, anaphylaxis) to other biologic... [+28]

Read more